As a result, they are increasingly used in patients with both diabetes and cardiovascular disease
This structural modification suggests that similar analgesic effects can be mediated by these GLP-1 analogs, even in the absence of the exendin 2029 sequence
Using a swine experimental model, Moberly et al
Since control of diabetes and obesity are significant health outcome risk factors, it is conceivable that the shortages and high cost of GLP1 agonists will exacerbate existing health disparities. David Cutler, MD His perspective echoed what Ma told us, namely that [o]ne of the biggest bottlenecks with GLP-1RA access is cost and insurance. Even if a doctor prescribes [this type of drug], patients cannot obtain it if their insurance does not cover it, which could worsen disparities, especially for those with public insurance or in underserved populations, he also emphasized
it's just spread across several days instead of landing in one shot